Jpmorgan Chase & CO Tyra Biosciences, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 91,115 shares of TYRA stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
91,115
Previous 368,647
75.28%
Holding current value
$1.2 Million
Previous $8.67 Million
85.39%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding TYRA
# of Institutions
112Shares Held
43.1MCall Options Held
3.8KPut Options Held
6K-
Ra Capital Management, L.P. Boston, MA10.6MShares$140 Million2.39% of portfolio
-
Canaan Partners Xi LLC Menlo Park, CA4.18MShares$55 Million97.27% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$53.7 Million89.47% of portfolio
-
Nextech Invest Ag4.06MShares$53.4 Million10.51% of portfolio
-
Bvf Inc San Francisco, CA3.94MShares$51.9 Million2.05% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $553M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...